PriceTargets.com logo

NYSE:MDC - M.D.C. Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $65.40
  • Forecasted Upside: 9.51 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$59.72 As of 04/21/2021 11:02 AM ET
▲ +0.79 (1.34%)
1 month | 3 months | 12 months
Get New M.D.C. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$65.40
▲ +9.51% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for M.D.C. in the last 3 months. The average price target is $65.40, with a high forecast of $71.00 and a low forecast of $61.00. The average price target represents a 9.51% upside from the last price of $59.72.
Buy
The current consensus among 6 polled investment analysts is to buy stock in M.D.C.. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2019
  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2020
  • 1 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
4/26/2020
  • 1 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
7/25/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
10/23/2020
  • 1 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
1/21/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/22/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/21/2021

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/21/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$65.00N/A
i
4/15/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$65.00High
i
3/22/2021Wolfe ResearchInitiated CoveragePeer PerformLow
i
3/18/2021Bank of AmericaReiterated RatingNeutral ➝ Underperform$63.00High
i
3/16/2021Wolfe ResearchInitiated CoveragePeer PerformLow
i
3/12/2021Bank of AmericaDowngradeNeutral ➝ Underperform$63.00Medium
i
1/25/2021Raymond JamesBoost Price TargetStrong-Buy$61.00 ➝ $71.00Low
i
1/5/2021Bank of AmericaDowngradeBuy ➝ NeutralN/A
i
10/30/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$46.00High
i
10/26/2020Zelman & AssociatesDowngradeBuy ➝ HoldMedium
i
10/8/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$50.00 ➝ $67.00High
i
9/15/2020Bank of AmericaUpgradeNeutral ➝ Buy$57.00High
i
7/29/2020JPMorgan Chase & Co.Boost Price TargetNeutral$38.50 ➝ $50.00Medium
i
7/29/2020Evercore ISIUpgradeIn-Line ➝ Outperform$61.00High
i
Rating by Trey Morrish at Evercore ISI
4/9/2020Raymond JamesLower Price TargetStrong-Buy$52.00 ➝ $35.00High
i
4/2/2020WedbushLower Price TargetNeutral$40.00 ➝ $29.00Medium
i
3/23/2020Bank of AmericaDowngradeHoldHigh
i
Rating by John Lovallo at Bank of America Co.
3/18/2020JPMorgan Chase & Co.Lower Price TargetNeutral$46.50 ➝ $22.00High
i
1/31/2020Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$39.00 ➝ $42.00High
i
10/31/2019Zelman & AssociatesDowngradeBuy ➝ HoldMedium
i
10/31/2019CfraUpgradeHold ➝ BuyLow
i
9/13/2019WedbushBoost Price TargetNeutral$35.00 ➝ $41.00High
i
9/13/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$42.00 ➝ $49.00High
i
8/1/2019WedbushBoost Price TargetNeutral$30.00 ➝ $35.00Low
i
7/8/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralHigh
i
5/1/2019WedbushReiterated RatingNeutral$30.00High
i
11/12/2018WedbushBoost Price TargetNeutral ➝ Neutral$31.00 ➝ $32.00Low
i
11/2/2018WedbushLower Price TargetNeutral ➝ Neutral$34.00 ➝ $31.00Low
i
10/25/2018Evercore ISIUpgradeOutperform$33.00 ➝ $31.00High
i
10/11/2018Bank of AmericaSet Price TargetBuy$34.00Medium
i
Rating by John Lovallo at Bank of America Co.
9/21/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$38.00 ➝ $32.00High
i
8/2/2018WedbushLower Price TargetNeutral ➝ Neutral$34.00 ➝ $33.00Medium
i
Rating by J. Mccanless at Wedbush
8/2/2018Bank of AmericaUpgradeUnderperform ➝ Buy$36.00 ➝ $42.00Low
i
7/13/2018JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$36.00Low
i
5/8/2018Raymond JamesReiterated RatingOutperform ➝ Buy$35.00 ➝ $39.00Low
i
Rating by Buck Horne at Raymond James
5/4/2018Zelman & AssociatesUpgradeHold ➝ BuyLow
i
5/4/2018WedbushReiterated RatingNeutral$33.00 ➝ $30.00High
i
Rating by J. Mccanless at Wedbush
5/4/2018UBS GroupReiterated RatingBuy$32.00 ➝ $35.00High
i
3/19/2018WedbushInitiated CoverageNeutral ➝ Neutral$30.00Low
i
Rating by J. Mccanless at Wedbush
3/13/2018UBS GroupUpgradeSell ➝ Buy$32.00High
i
2/13/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$35.00Low
i
Rating by Buck Horne at Raymond James
2/13/2018UBS GroupUpgradeMarket Perform ➝ OutperformLow
i
2/2/2018Bank of AmericaBoost Price TargetUnderperform ➝ Underperform$31.00 ➝ $34.00Medium
i
1/17/2018UBS GroupReiterated RatingSell ➝ Sell$30.00 ➝ $32.00Low
i
11/6/2017UBS GroupLower Price TargetSell$34.00 ➝ $32.00N/A
i
11/3/2017CitigroupLower Price TargetNeutral$37.00 ➝ $34.00N/A
i
10/25/2017UBS GroupInitiated CoverageSell$34.00N/A
i
9/26/2017KeyCorpReiterated RatingHoldLow
i
8/30/2017Wells Fargo & CompanyUpgradeUnderperform ➝ Market Perform$30.00Low
i
Rating by Stephen East at Wells Fargo & Company
8/25/2017KeyCorpReiterated RatingHoldLow
i
8/3/2017Deutsche Bank AktiengesellschaftBoost Price TargetHold$27.00 ➝ $33.00Low
i
6/28/2017Bank of AmericaReiterated RatingUnderperform$24.00 ➝ $27.00Low
i
5/16/2017Wells Fargo & CompanyDowngradeMarket Perform ➝ Underperform$30.00Low
i
5/10/2017CitigroupDowngradeBuy ➝ NeutralLow
i
3/17/2017FBN SecuritiesDowngradeOutperform ➝ Sector PerformHigh
i
1/30/2017Evercore ISIDowngradeHold ➝ Sell$26.00N/A
i
11/14/2016Evercore ISIInitiated CoverageHold$28.00N/A
i
9/28/2016Wells Fargo & CompanyInitiated CoverageMarket PerformN/A
i
8/8/2016Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$28.00 ➝ $27.00N/A
i
8/5/2016CitigroupBoost Price TargetBuy$27.00 ➝ $29.00N/A
i
7/5/2016ArgusReiterated RatingHoldN/A
i
5/16/2016Sterne Agee CRTReiterated RatingNeutralN/A
i
Rating by J. Mccanless at Sterne Agee CRT
5/16/2016Deutsche Bank AktiengesellschaftLower Price TargetBuy$30.00 ➝ $28.00N/A
i
Rating by Nishu Sood at Deutsche Bank Aktiengesellschaft
(Data available from 4/21/2016 forward)
M.D.C. logo
M.D.C. Holdings, Inc., through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name. The company conducts its homebuilding operations in Arizona, California, Nevada, Washington, Oregon, Colorado, Utah, Virginia, Maryland, and Florida. Its financial services operations comprise originating mortgage loans primarily for homebuyers; providing insurance coverage primarily to its homebuilding subsidiaries and subcontractors for homes sold by its homebuilding subsidiaries, and for work performed in completed subdivisions; acting as a re-insurer on the claims; selling third-party personal property and casualty insurance products to homebuyers; and offering title agency services to homebuilding subsidiaries and customers in Colorado, Florida, Maryland, Nevada, and Virginia. M.D.C. Holdings, Inc. was founded in 1972 and is headquartered in Denver, Colorado.
Read More

Today's Range

Now: $59.72
$59.17
$59.98

50 Day Range

MA: $58.49
$51.54
$62.13

52 Week Range

Now: $59.72
$20.38
$62.61

Volume

674 shs

Average Volume

626,760 shs

Market Capitalization

$3.89 billion

P/E Ratio

12.49

Dividend Yield

2.42%

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of M.D.C.?

The following equities research analysts have issued research reports on M.D.C. in the last twelve months: Bank of America Co., Evercore ISI, JPMorgan Chase & Co., Raymond James, Wells Fargo & Company, Wolfe Research, Zacks Investment Research, and Zelman & Associates.
View the latest analyst ratings for MDC.

What is the current price target for M.D.C.?

5 Wall Street analysts have set twelve-month price targets for M.D.C. in the last year. Their average twelve-month price target is $65.40, suggesting a possible upside of 11.9%. Raymond James has the highest price target set, predicting MDC will reach $71.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $61.00 for M.D.C. in the next year.
View the latest price targets for MDC.

What is the current consensus analyst rating for M.D.C.?

M.D.C. currently has 1 sell rating, 2 hold ratings, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDC will outperform the market and that investors should add to their positions of M.D.C..
View the latest ratings for MDC.

What other companies compete with M.D.C.?

Other companies that are similar to M.D.C. include D.R. Horton, Lennar, NVR, PulteGroup, Toll Brothers, KB Home, Meritage Homes, Tri Pointe Homes, Cavco Industries, M/I Homes, Hovnanian Enterprises and Beazer Homes USA.

How do I contact M.D.C.'s investor relations team?

M.D.C.'s physical mailing address is 4350 S MONACO STREET SUITE 500, DENVER CO, 80237. The construction company's listed phone number is 303-773-1100 and its investor relations email address is [email protected] The official website for M.D.C. is www.mdcholdings.com.